WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H524756
CAS#: 105956-99-8 (HCl)
Description: Clinafloxacin is an antimicrobial antibiotic that displays broad-spectrum antibacterial activity against Gram-positive, Gram-negative, and anaerobic pathogens by inhibiting the bacterial regulatory enzyme DNA gyrase (IC50 = 0.92 µg/ml) as well as topoisomerase IV (IC50 = 1.62 µg/ml).
Hodoodo Cat#: H524756
Name: Clinafloxacin hydrochloride
CAS#: 105956-99-8 (HCl)
Chemical Formula: C17H18Cl2FN3O3
Exact Mass: 0.00
Molecular Weight: 402.250
Elemental Analysis: C, 50.76; H, 4.51; Cl, 17.63; F, 4.72; N, 10.45; O, 11.93
Related CAS #: 105956-97-6 (free base) 105956-99-8 (HCl)
Synonym: Clinafloxacin hydrochloride; Clinafloxacin HCl; CI-960 HCl; UNII-G17M59V0FY; CI 960 HCl.
IUPAC/Chemical Name: (+-)-7-(3-Amino-1-pyrrolidinyl)-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid, monohydrochloride
InChi Key: BMACYHMTJHBPOX-UHFFFAOYSA-N
InChi Code: InChI=1S/C17H17ClFN3O3.ClH/c18-13-14-10(5-12(19)15(13)21-4-3-8(20)6-21)16(23)11(17(24)25)7-22(14)9-1-2-9;/h5,7-9H,1-4,6,20H2,(H,24,25);1H
SMILES Code: c1c2c(c(c(c1F)N3CCC(C3)N)Cl)n(cc(c2=O)C(=O)O)C4CC4.Cl
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 402.25 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Majalekar PP, Shirote PJ. Fluoroquinolones: Blessings Or Curses. Curr Drug Targets. 2020;21(13):1354-1370. doi: 10.2174/1389450121666200621193355. PMID: 32564750.
2: Matuschka PR, Vissing RS. Clinafloxacin-theophylline drug interaction. Ann Pharmacother. 1995 Apr;29(4):378-80. doi: 10.1177/106002809502900407. PMID: 7633015.
3: Randinitis EJ, Alvey CW, Koup JR, Rausch G, Abel R, Bron NJ, Hounslow NJ, Vassos AB, Sedman AJ. Drug interactions with clinafloxacin. Antimicrob Agents Chemother. 2001 Sep;45(9):2543-52. doi: 10.1128/AAC.45.9.2543-2552.2001. PMID: 11502527; PMCID: PMC90690.
4: Siami FS, LaFleur BJ, Siami GA. Clinafloxacin versus piperacillin/tazobactam in the treatment of severe skin and soft-tissue infections in adults at a Veterans Affairs medical center. Clin Ther. 2002 Jan;24(1):59-72. doi: 10.1016/s0149-2918(02)85005-6. PMID: 11833836.
5: Nord CE. Use of newer quinolones for the treatment of intraabdominal infections: focus on clinafloxacin. Infection. 1999 May-Jun;27(3):166-72. doi: 10.1007/BF02561522. PMID: 10378126.
6: Siami G, Christou N, Eiseman I, Tack KJ; Severe Skin and Soft Tissue Infections Study Group. Clinafloxacin versus piperacillin-tazobactam in treatment of patients with severe skin and soft tissue infections. Antimicrob Agents Chemother. 2001 Feb;45(2):525-31. doi: 10.1128/AAC.45.2.525-531.2001. PMID: 11158750; PMCID: PMC90322.
7: Randinitis EJ, Koup JR, Rausch G, Abel R, Bron NJ, Hounslow NJ, Vassos AB, Sedman AJ. Clinafloxacin pharmacokinetics in subjects with various degrees of renal function. Antimicrob Agents Chemother. 2001 Sep;45(9):2536-42. doi: 10.1128/AAC.45.9.2536-2542.2001. PMID: 11502526; PMCID: PMC90689.
8: Glauser MP, Brennscheidt U, Cornely O, Grigg A, Figuera A, Keyserling C, Trostmann U, Welling L, Tack K. Clinafloxacin monotherapy (CI-960) versus ceftazidime plus amikacin for empirical treatment of febrile neutropenic cancer patients. Clin Microbiol Infect. 2002 Jan;8(1):14-25. doi: 10.1046/j.1198-743x.2001.00338.x. PMID: 11906496.
9: Goldstein EJ. Possible role for the new fluoroquinolones (levofloxacin, grepafloxacin, trovafloxacin, clinafloxacin, sparfloxacin, and DU-6859a) in the treatment of anaerobic infections: review of current information on efficacy and safety. Clin Infect Dis. 1996 Dec;23 Suppl 1:S25-30. doi: 10.1093/clinids/23.supplement_1.s25. PMID: 8953103.
10: Randinitis EJ, Brodfuehrer JI, Eiseman I, Vassos AB. Pharmacokinetics of clinafloxacin after single and multiple doses. Antimicrob Agents Chemother. 2001 Sep;45(9):2529-35. doi: 10.1128/AAC.45.9.2529-2535.2001. PMID: 11502525; PMCID: PMC90688.
11: Vila J, Ribera A, Marco F, Ruiz J, Mensa J, Chaves J, Hernandez G, Jimenez De Anta MT. Activity of clinafloxacin, compared with six other quinolones, against Acinetobacter baumannii clinical isolates. J Antimicrob Chemother. 2002 Mar;49(3):471-7. doi: 10.1093/jac/49.3.471. PMID: 11864947.
12: Humphrey GH, Shapiro MA, Randinitis EJ, Guttendorf RJ, Brodfuehrer JI. Pharmacokinetics of clinafloxacin enantiomers in humans. J Clin Pharmacol. 1999 Nov;39(11):1143-50. PMID: 10579144.
13: Levine DP, Holley HP, Eiseman I, Willcox P, Tack K. Clinafloxacin for the treatment of bacterial endocarditis. Clin Infect Dis. 2004 Mar 1;38(5):620-31. doi: 10.1086/381670. Epub 2004 Feb 17. PMID: 14986244.
14: Nagai K, Davies TA, Pankuch GA, Dewasse BE, Jacobs MR, Appelbaum PC. In vitro selection of resistance to clinafloxacin, ciprofloxacin, and trovafloxacin in Streptococcus pneumoniae. Antimicrob Agents Chemother. 2000 Oct;44(10):2740-6. doi: 10.1128/AAC.44.10.2740-2746.2000. PMID: 10991854; PMCID: PMC90145.
15: Balwan A, Nicolau DP, Wungwattana M, Zuckerman JB, Waters V. Clinafloxacin for Treatment of Burkholderia cenocepacia Infection in a Cystic Fibrosis Patient. Antimicrob Agents Chemother. 2015 Dec 31;60(1):1-5. doi: 10.1128/AAC.masthead.60-1. PMID: 26722110; PMCID: PMC4704148.
16: Oh H, Nord CE, Barkholt L, Hedberg M, Edlund C. Ecological disturbances in intestinal microflora caused by clinafloxacin, an extended-spectrum quinolone. Infection. 2000 Sep;28(5):272-7. doi: 10.1007/s150100070018. PMID: 11073132.
17: Deshpande LM, Diekema DJ, Jones RN. Comparative activity of clinafloxacin and nine other compounds tested against 2000 contemporary clinical isolates from patients in United States hospitals. Diagn Microbiol Infect Dis. 1999 Sep;35(1):81-8. doi: 10.1016/s0732-8893(99)00020-6. PMID: 10529885.
18: Winston DJ, Lazarus HM, Beveridge RA, Hathorn JW, Gucalp R, Ramphal R, Chow AW, Ho WG, Horn R, Feld R, Louie TJ, Territo MC, Blumer JL, Tack KJ. Randomized, double-blind, multicenter trial comparing clinafloxacin with imipenem as empirical monotherapy for febrile granulocytopenic patients. Clin Infect Dis. 2001 Feb 1;32(3):381-90. doi: 10.1086/318500. Epub 2001 Jan 30. PMID: 11170945.
19: Zaman MM, Landman D, Burney S, Quale JM. Treatment of experimental endocarditis due to multidrug-resistant Enterococcus faecium with clinafloxacin and penicillin. J Antimicrob Chemother. 1996 Jan;37(1):127-32. doi: 10.1093/jac/37.1.127. PMID: 8647753.
20: Buglak AA, Shanin IA, Eremin SA, Lei HT, Li X, Zherdev AV, Dzantiev BB. Ciprofloxacin and Clinafloxacin Antibodies for an Immunoassay of Quinolones: Quantitative Structure⁻Activity Analysis of Cross-Reactivities. Int J Mol Sci. 2019 Jan 11;20(2):265. doi: 10.3390/ijms20020265. PMID: 30641870; PMCID: PMC6359390.
